Loading...

Indivior PLC

INVVYPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$21.85
$0.00(0.00%)

Indivior PLC (INVVY) Financial Performance & Income Statement Overview

Review Indivior PLC (INVVY) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
8.69%
8.69%
Operating Income Growth
900.00%
900.00%
Net Income Growth
1150.00%
1150.00%
Operating Cash Flow Growth
111.43%
111.43%
Operating Margin
20.27%
20.27%
Gross Margin
83.99%
83.99%
Net Profit Margin
10.90%
10.90%
ROE
-48.35%
48.35%
ROIC
60.10%
60.10%

Indivior PLC (INVVY) Income Statement & Financial Overview

Analyze Indivior PLC’s INVVY earnings with segmented quarterly and yearly financial statement figures.

MetricQ3 2024Q2 2024Q1 2024Q4 2023
Revenue$307.00M$299.61M$282.74M$300.65M
Cost of Revenue$69.00M$116.24M$52.76M$55.41M
Gross Profit$238.00M$183.37M$229.97M$245.24M
Gross Profit Ratio$0.78$0.61$0.81$0.82
R&D Expenses$22.63M$27.05M$27.88M$30.78M
SG&A Expenses$208.00M$121.25M$135.39M$152.89M
Operating Expenses$234.00M$148.30M$163.27M$183.67M
Total Costs & Expenses$303.00M$264.54M$216.03M$239.08M
Interest Income$5.00M$6.00M$6.00M$10.00M
Interest Expense$10.00M$9.00M$8.00M$8.00M
Depreciation & Amortization-$10.00M$25.05M$8.96M$9.23M
EBITDA$9.00M-$101.21M$80.64M$70.80M
EBITDA Ratio$0.03$0.20$0.27$0.24
Operating Income$4.00M$35.07M$66.70M$61.57M
Operating Income Ratio$0.01$0.12$0.24$0.20
Other Income/Expenses (Net)-$5.00M-$3.00M-$2.00M$1.59M
Income Before Tax-$1.00M-$135.27M$62.72M$62.59M
Income Before Tax Ratio-$0.003-$0.45$0.22$0.21
Income Tax Expense-$5.00M-$28.06M$15.93M$7.18M
Net Income$4.00M-$107.22M$47.00M$54.00M
Net Income Ratio$0.01-$0.36$0.17$0.18
EPS$0.03-$0.80$0.34$0.40
Diluted EPS$0.03-$0.80$0.34$0.39
Weighted Avg Shares Outstanding$132.10M$134.85M$135.74M$137.32M
Weighted Avg Shares Outstanding (Diluted)$133.55M$134.85M$138.71M$141.95M

The company's financials show resilient growth, with revenue advancing from $300.65M in Q4 2023 to $307.00M in Q3 2024. Gross profit remained healthy with margins at 78% in Q3 2024 compared to 82% in Q4 2023. Operating income hit $4.00M last quarter, sustaining a consistent 1% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $9.00M. Net income rose to $4.00M, while earnings per share reached $0.03. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;